Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone

Trial Profile

Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs Aripiprazole (Primary) ; Olanzapine (Primary) ; Paliperidone (Primary) ; Quetiapine (Primary) ; Risperidone (Primary)
  • Indications Bipolar disorders; Depressive disorders; Psychotic disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Nov 2016 New trial record
    • 01 Nov 2016 Results published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top